Cargando…

The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial

BACKGROUND: The ventilatory ratio (VR, [minute ventilation × PaCO(2)]/[predicted body weight × 100 × 37.5]) is associated with mortality in ARDS. The aims of this study were to test whether baseline disease severity or neuromuscular blockade (NMB) modified the relationship between VR and mortality....

Descripción completa

Detalles Bibliográficos
Autores principales: Monteiro, Ana Carolina Costa, Vangala, Sitaram, Wick, Katherine D., Delucchi, Kevin L., Siegel, Emily R., Thompson, B. Taylor, Liu, Kathleen D., Sapru, Anil, Sinha, Pratik, Matthay, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521854/
https://www.ncbi.nlm.nih.gov/pubmed/36175982
http://dx.doi.org/10.1186/s13054-022-04179-7
_version_ 1784799933172285440
author Monteiro, Ana Carolina Costa
Vangala, Sitaram
Wick, Katherine D.
Delucchi, Kevin L.
Siegel, Emily R.
Thompson, B. Taylor
Liu, Kathleen D.
Sapru, Anil
Sinha, Pratik
Matthay, Michael A.
author_facet Monteiro, Ana Carolina Costa
Vangala, Sitaram
Wick, Katherine D.
Delucchi, Kevin L.
Siegel, Emily R.
Thompson, B. Taylor
Liu, Kathleen D.
Sapru, Anil
Sinha, Pratik
Matthay, Michael A.
author_sort Monteiro, Ana Carolina Costa
collection PubMed
description BACKGROUND: The ventilatory ratio (VR, [minute ventilation × PaCO(2)]/[predicted body weight × 100 × 37.5]) is associated with mortality in ARDS. The aims of this study were to test whether baseline disease severity or neuromuscular blockade (NMB) modified the relationship between VR and mortality. METHODS: This was a post hoc analysis of the PETAL-ROSE trial, which randomized moderate-to-severe ARDS patients to NMB or control. Survival among patients with different VR trajectories or VR cutoff above and below the median was assessed by Kaplan–Meier analysis. The relationships between single-day or 48-h VR trajectories with 28- or 90-day mortality were tested by logistic regression. Randomization allocation to NMB and markers of disease severity were tested as confounders by multivariable regression and interaction term analyses. RESULTS: Patients with worsening VR trajectories had significantly lower survival compared to those with improving VR (n = 602, p < 0.05). Patients with VR > 2 (median) at day 1 had a significantly lower 90-day survival compared to patients with VR ≤ 2 (HR 1.36, 95% CI 1.10–1.69). VR at day 1 was significantly associated with 28-day mortality (OR = 1.40, 95% CI 1.15–1.72). There was no interaction between NMB and VR for 28-day mortality. APACHE-III had a significant interaction with VR at baseline for the outcome of 28-day mortality, such that the relationship between VR and mortality was stronger among patients with lower APACHE-III. There was a significant association between rising VR trajectory and mortality that was independent of NMB, baseline PaO(2)/FiO(2) ratio and generalized markers of disease severity (Adjusted OR 1.81, 95% CI 1.28–2.84 for 28-day and OR 2.07 95% CI 1.41–3.10 for 90-day mortality). APACHE-III and NMB were not effect modifiers in the relationship between VR trajectory and mortality. CONCLUSIONS: Elevated baseline and day 1 VR were associated with higher 28-day mortality. The relationship between baseline VR and mortality was stronger among patients with lower APACHE-III. APACHE-III was not an effect modifier for the relationship between VR trajectory and mortality, so that the VR trajectory may be optimally suited for prognostication and predictive enrichment. VR was not different between patients randomized to NMB or control, indicating that VR can be utilized without correcting for NMB. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-022-04179-7.
format Online
Article
Text
id pubmed-9521854
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95218542022-09-30 The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial Monteiro, Ana Carolina Costa Vangala, Sitaram Wick, Katherine D. Delucchi, Kevin L. Siegel, Emily R. Thompson, B. Taylor Liu, Kathleen D. Sapru, Anil Sinha, Pratik Matthay, Michael A. Crit Care Research BACKGROUND: The ventilatory ratio (VR, [minute ventilation × PaCO(2)]/[predicted body weight × 100 × 37.5]) is associated with mortality in ARDS. The aims of this study were to test whether baseline disease severity or neuromuscular blockade (NMB) modified the relationship between VR and mortality. METHODS: This was a post hoc analysis of the PETAL-ROSE trial, which randomized moderate-to-severe ARDS patients to NMB or control. Survival among patients with different VR trajectories or VR cutoff above and below the median was assessed by Kaplan–Meier analysis. The relationships between single-day or 48-h VR trajectories with 28- or 90-day mortality were tested by logistic regression. Randomization allocation to NMB and markers of disease severity were tested as confounders by multivariable regression and interaction term analyses. RESULTS: Patients with worsening VR trajectories had significantly lower survival compared to those with improving VR (n = 602, p < 0.05). Patients with VR > 2 (median) at day 1 had a significantly lower 90-day survival compared to patients with VR ≤ 2 (HR 1.36, 95% CI 1.10–1.69). VR at day 1 was significantly associated with 28-day mortality (OR = 1.40, 95% CI 1.15–1.72). There was no interaction between NMB and VR for 28-day mortality. APACHE-III had a significant interaction with VR at baseline for the outcome of 28-day mortality, such that the relationship between VR and mortality was stronger among patients with lower APACHE-III. There was a significant association between rising VR trajectory and mortality that was independent of NMB, baseline PaO(2)/FiO(2) ratio and generalized markers of disease severity (Adjusted OR 1.81, 95% CI 1.28–2.84 for 28-day and OR 2.07 95% CI 1.41–3.10 for 90-day mortality). APACHE-III and NMB were not effect modifiers in the relationship between VR trajectory and mortality. CONCLUSIONS: Elevated baseline and day 1 VR were associated with higher 28-day mortality. The relationship between baseline VR and mortality was stronger among patients with lower APACHE-III. APACHE-III was not an effect modifier for the relationship between VR trajectory and mortality, so that the VR trajectory may be optimally suited for prognostication and predictive enrichment. VR was not different between patients randomized to NMB or control, indicating that VR can be utilized without correcting for NMB. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-022-04179-7. BioMed Central 2022-09-29 /pmc/articles/PMC9521854/ /pubmed/36175982 http://dx.doi.org/10.1186/s13054-022-04179-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Monteiro, Ana Carolina Costa
Vangala, Sitaram
Wick, Katherine D.
Delucchi, Kevin L.
Siegel, Emily R.
Thompson, B. Taylor
Liu, Kathleen D.
Sapru, Anil
Sinha, Pratik
Matthay, Michael A.
The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
title The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
title_full The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
title_fullStr The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
title_full_unstemmed The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
title_short The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
title_sort prognostic value of early measures of the ventilatory ratio in the ards rose trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521854/
https://www.ncbi.nlm.nih.gov/pubmed/36175982
http://dx.doi.org/10.1186/s13054-022-04179-7
work_keys_str_mv AT monteiroanacarolinacosta theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT vangalasitaram theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT wickkatherined theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT delucchikevinl theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT siegelemilyr theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT thompsonbtaylor theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT liukathleend theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT sapruanil theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT sinhapratik theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT matthaymichaela theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT theprognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT monteiroanacarolinacosta prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT vangalasitaram prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT wickkatherined prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT delucchikevinl prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT siegelemilyr prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT thompsonbtaylor prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT liukathleend prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT sapruanil prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT sinhapratik prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT matthaymichaela prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial
AT prognosticvalueofearlymeasuresoftheventilatoryratiointheardsrosetrial